Located at the Höchst Industrial Park in Frankfurt am Main, the facility adds to the 22 sites the group have worldwide, in which the initial focus will be on developing microorganisms to produce varieties of organic compounds.
“Investing in Gelita's Biotech Hub is a clear commitment to biotechnology, a key and future-oriented 21st-century technology that offers enormous innovation potential,” states Dr Sven Abend, CEO of Gelita.
“It allows us to meet the growing demand of international markets sustainably and with new offers.
“At the same time, the new research laboratory underlines our commitment to innovation in our markets and our goal of sustainable, profitable growth."
High growth rates
The collagen protein specialists, which are headquartered in Eberbach, Germany, add that its collagen peptides from animal raw materials have recorded high growth rates in recent years.
The company says that it plans to expand its expertise in the field of biotechnology - a move that will secure its core business in the long term and open new, lucrative market segments.
Gelita’s decision to locate the centre in Frankfurt means it will be in close proximity to the biotech-based industrial and research landscape of the Main metropolis.
With plans to expand the team in the coming years, the firm hopes to receive applications from well-trained, experienced specialists.
“Biotechnology overcomes the limitations of conventional manufacturing processes,” says Dr Christoph Schorsch, Head of GELITA's new biotech hub.
“Biotechnologically produced proteins enable us to manufacture alternatives of consistently high quality and with optimised properties - in some cases even more resource-efficiently and sustainably than by conventional means."
